891785-30-1

Basic information

• Product Name: 6-BroMo-3-fluoroisoquinoline
• Synonyms: 6-BroMo-3-fluoroisoquinoline
• CAS NO: 891785-30-1
• Molecular Formula: C9H5BrFN
• Molecular Weight: 226.0451032
• Mol File: 891785-30-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 326.4±22.0 °C(Predicted)
• Appearance: /
• Density: 1.647±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 1.02±0.38(Predicted)
• CAS DataBase Reference: 6-BroMo-3-fluoroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BroMo-3-fluoroisoquinoline(891785-30-1)
• EPA Substance Registry System: 6-BroMo-3-fluoroisoquinoline(891785-30-1)

Safety Data

• Hazardous Substances Data: 891785-30-1(Hazardous Substances Data)

Usage

General Description

6-Bromo-3-fluoroisoquinoline is a chemical compound with the molecular formula C9H5BrFN. It is an isoquinoline derivative with bromine and fluorine substituents. 6-BroMo-3-fluoroisoquinoline is commonly used in the pharmaceutical industry for the synthesis of various biologically active molecules and materials. It has been found to exhibit an array of interesting pharmacological properties, including antimicrobial and antitumor activities. Additionally, 6-bromo-3-fluoroisoquinoline has been investigated for its potential use as a building block in the development of new drugs and therapeutic agents. Overall, this compound has garnered significant interest in the scientific community due to its versatile applications in medicinal chemistry and drug discovery.

Upstream product

• 891785-28-7 6-bromo-isoquinolin-3-ylamine 
• 552331-06-3 6-bromo-3-chloro-isoquinoline 
• 934343-53-0 benzyl-(6-bromo-isoquinolin-3-yl)-amine 

Downstream Products

• 1105710-34-6 3-fluoroisoquinolin-6-ylboronic acid 
• 1574396-46-5 6-bromo-N-(1,3-dimethyl-1H-pyrazol-5-yl)-isoquinolin-3-amine 

Relevant articles and documents

Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3)

PRMT3 catalyzes the asymmetric dimethylation of arginine residues of various proteins. It is crucial for maturation of ribosomes and has been implicated in several diseases. We recently disclosed a highly potent, selective, and cell-active allosteric inhibitor of PRMT3, compound 4. Here, we report comprehensive structure-activity relationship studies that target the allosteric binding site of PRMT3. We conducted design, synthesis, and evaluation of novel compounds in biochemical, selectivity, and cellular assays that culminated in the discovery of 4 and other highly potent (IC50 values: ～10-36 nM), selective, and cell-active allosteric inhibitors of PRMT3 (compounds 29, 30, 36, and 37). In addition, we generated compounds that are very close analogs of these potent inhibitors but displayed drastically reduced potency as negative controls (compounds 49-51). These inhibitors and negative controls are valuable chemical tools for the biomedical community to further investigate biological functions and disease associations of PRMT3.

FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE

The invention relates to thiazole compounds of Formula (I) and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

HETEROCYCLIC MODULATORS OF PKB

The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein Formula (I). The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.